Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

Rhea-AI Summary

Mersana Therapeutics (NASDAQ: MRSN), a clinical-stage biopharmaceutical company specializing in antibody-drug conjugates (ADCs) for cancer treatment, has announced its participation in the upcoming Guggenheim SMID Cap Biotech Conference. The company's management will engage in a fireside chat scheduled for February 6, 2025, at 1:30 p.m. ET.

Investors and interested parties can access a live webcast of the presentation through Mersana's website (www.mersana.com) in the Investors & Media section. The recorded session will remain available for approximately 90 days after the event.

CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on February 6, 2025 at 1:30 p.m. ET. A live webcast of this event will be available on the Investors & Media section of Mersana’s website at www.mersana.com, and an archived replay will be available for approximately 90 days following the event.

About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that are generating a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline includes Emi-Le (emiltatug ledadotin; XMT-1660), a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). Mersana routinely posts information that may be useful to investors on the “Investors & Media” section of its website at www.mersana.com.

Contact:
Jason Fredette
617-498-0020
jason.fredette@mersana.com

FAQ

When is Mersana Therapeutics (MRSN) presenting at the Guggenheim SMID Cap Biotech Conference 2025?

Mersana Therapeutics will present at the Guggenheim SMID Cap Biotech Conference on February 6, 2025, at 1:30 p.m. ET.

How can investors access Mersana's (MRSN) Guggenheim Conference presentation?

Investors can access the live webcast through the Investors & Media section of Mersana's website at www.mersana.com.

How long will the replay of MRSN's Guggenheim Conference presentation be available?

The archived replay of the presentation will be available for approximately 90 days following the event.

What is Mersana Therapeutics' (MRSN) main focus in cancer treatment?

Mersana Therapeutics focuses on discovering and developing antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need.